APA

Martin M., Brase J. C., Ruiz A., Prat A., Kronenwett R., Calvo L., Petry C., Bernard P. S., Ruiz-Borrego M., Weber K. E., Rodriguez C. A., Alvarez I. M., Segui M. A., Perou C. M., Casas M., Carrasco E., Caballero R. & Rodriguez-Lescure A. (20161213). Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. : Breast cancer research and treatment.

Chicago

Martin Miguel, Brase Jan C, Ruiz Amparo, Prat Aleix, Kronenwett Ralf, Calvo Lourdes, Petry Christoph, Bernard Philip S, Ruiz-Borrego Manuel, Weber Karsten E, Rodriguez César A, Alvarez Isabel M, Segui Miguel A, Perou Charles M, Casas Maribel, Carrasco Eva, Caballero Rosalía and Rodriguez-Lescure Alvaro. 20161213. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. : Breast cancer research and treatment.

Harvard

Martin M., Brase J. C., Ruiz A., Prat A., Kronenwett R., Calvo L., Petry C., Bernard P. S., Ruiz-Borrego M., Weber K. E., Rodriguez C. A., Alvarez I. M., Segui M. A., Perou C. M., Casas M., Carrasco E., Caballero R. and Rodriguez-Lescure A. (20161213). Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. : Breast cancer research and treatment.

MLA

Martin Miguel, Brase Jan C, Ruiz Amparo, Prat Aleix, Kronenwett Ralf, Calvo Lourdes, Petry Christoph, Bernard Philip S, Ruiz-Borrego Manuel, Weber Karsten E, Rodriguez César A, Alvarez Isabel M, Segui Miguel A, Perou Charles M, Casas Maribel, Carrasco Eva, Caballero Rosalía and Rodriguez-Lescure Alvaro. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. : Breast cancer research and treatment. 20161213.